• Trending
  • Latest
    Sign in Sign up
    • Log In
    • Register
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Mashup Score: 2
      Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A | NEJM - 5 month(s) ago

      Severe hemophilia A is managed with factor VIII replacement or hemostatic products that stop or prevent bleeding. Data on gene therapy with hematopoietic stem-cell (HSC)–based expression of factor …

      Source: www.nejm.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	albertomussetti
        albertomussetti

        Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A | New England Journal of Medicine https://t.co/MFaDJ0giEE

    • Mashup Score: 3
      Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A | NEJM - 5 month(s) ago

      Severe hemophilia A is managed with factor VIII replacement or hemostatic products that stop or prevent bleeding. Data on gene therapy with hematopoietic stem-cell (HSC)–based expression of factor …

      Source: www.nejm.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	albertomussetti
        albertomussetti

        Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A | New England Journal of Medicine https://t.co/IRZf1laqES

    • Mashup Score: 8
      Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease - 6 month(s) ago

      Key PointsCD3×CD3 tetravalent antibodies cure GVHD in xenogeneic mouse models and warrant further investigation in more clinically relevant models.

      Source: ashpublications.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	albertomussetti
        albertomussetti

        Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease https://t.co/bVNeHi93dg

    • Mashup Score: 18
      Paper: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial - 6 month(s) ago

      Program: Late-breaking Abstracts Session: Late-Breaking Abstracts Session Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, Lymphoid Malignancies 1 Medica l College of Wisconsin, Milwaukee, WI 2 Dana-Farber Cancer Institute / ECOG-ACRIN Biostatistics, Bostin, MA 3 Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 4 Emory University / Winship Cancer Institute, Atlanta, GA 5 University of

      Source: ash.confex.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	albertomussetti
        albertomussetti

        Stop ASCT for MCL...another evidence https://t.co/MyUi5Xj692

    • Mashup Score: 52
      Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study - 6 month(s) ago

      Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in CR1 aged 60-75 years were registered and a donor search initiated. After one consolidation cycle, patients with a matched donor were randomized to HCT with fludarabine/low-dose total body irradiation and cyclosporine/mycophenolate mofetil immunosuppression or conventional non-HCT. Primary outcome was restricted mean leukemia-free survival (RM-LFS) up to 5 years. Between 2010 and 2017, 245 patients (median age 67 years) were registered at CR1. After one consolidation, 26.9% of patients failed inclusion criteria. Of the 179 (73%) patients still on study, 75.4% had an HLA identical donor. Ten ineligible patients were excluded, and 125 randomized to HCT (N=83) or non-HCT (N=42). The primary outcome RM-LFS up to 5 years was 24.5 months (95% confidence inte

      Source: haematologica.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	albertomussetti
        albertomussetti

        Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study | Haematologica https://t.co/LCXab2JBEb

    • Mashup Score: 1
      Artificial Intelligence–Based Copilots to Generate Causal Evidence - 6 month(s) ago

      While there is growing consensus that real-world data should play a larger role in generating causal evidence for health care, it is less clear whether and how AI can help. Current approaches to AI…

      Source: ai.nejm.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	albertomussetti
        albertomussetti

        Artificial Intelligence–Based Copilots to Generate Causal Evidence | NEJM AI https://t.co/WmpW50EjZb

    • Mashup Score: 21
      Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma - 7 month(s) ago

      Abstract. Patients treated with chimeric antigen receptor T-cell (CAR-T) therapy are subject to profound immune suppression. Dynamics of immune reconstitution (IR) and impacts of IR on outcomes following infusion across CAR-T products are not well understood. Here, we profiled IR in 263 patients with relapsed/refractory large B-cell lymphoma receiving CAR-T therapy (axicabtagene ciloleucel 44.9%, lisocabtagene maraleucel 30.4%, tisagenlecleucel 24.7%). Following infusion, patients remain persistently immunosuppressed, with 48.1% having CD4+ T cell counts <200/µL and median CD3-19+ B cell counts remaining zero through 1 year after CAR-T. IR differences exist by product, with fastest CD4+ T cell recovery seen for tisagenlecleucel, driven primarily by more rapid recovery of the CD4+CCR7-45RA- effector memory subset. Natural killer cell, but not CD4+ T cell, recovery is significantly associated with favorable progression-free (HR: 0.647; 95% CI: 0.476-0.880) and overall survival (HR: 0.637

      Source: aacrjournals.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	albertomussetti
        albertomussetti

        Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma https://t.co/T7nngYI5wM

    • Mashup Score: 8
      T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities - 7 month(s) ago

      As the number of recipients of chimeric antigen receptor (CAR) T-cell therapies has rapidly increased, sporadic reports of T-cell lymphomas arising de novo

      Source: ashpublications.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	albertomussetti
        albertomussetti

        T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities https://t.co/UrKaHjDus1

    • Mashup Score: 19
      Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma - 7 month(s) ago

      Key PointsA lower circulating lymphocyte-to-monocyte ratio and proportion of B cells at apheresis predict a reduced likelihood of response to CAR-T.On expl

      Source: ashpublications.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	albertomussetti
        albertomussetti

        Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma https://t.co/cUSP8Ppr0E

    • Mashup Score: 2
      Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A | NEJM - 7 month(s) ago

      Severe hemophilia A is managed with factor VIII replacement or hemostatic products that stop or prevent bleeding. Data on gene therapy with hematopoietic stem-cell (HSC)–based expression of factor …

      Source: www.nejm.org
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	albertomussetti
        albertomussetti

        Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A | New England Journal of Medicine https://t.co/MFaDJ0giEE

    Load More

    Dr.Alberto Mussetti

    @albertomussetti

    Hematologist from Milan, working @ Institut Català d'Oncologia Science & Health News #hematology #transplant #lymphoma #immunotherapy #CAR #digitalmedicine

    ASCO 2025

    Advertisement

    Advertisement

    MashupMD
    © 2025 - Mashup Media LLC
    • Terms of Use
    • Privacy Policy
    • Cookie Settings